Future studies will be required to follow up on these findings to investigate how much later after reperfusion (i.e. beyond the 4 hr reperfusion ‘window’) hPMSCs may provide protection for stroke, currently the major limitation to administration of t-PA in stroke patients. This evidence concerns the gene PLAT and stroke disorder.